Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Arix Bioscience (ARIX) Ord

Sell:145.00p Buy:153.00p 0 Change: No change
Market closed Prices as at close on 27 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:145.00p
Buy:153.00p
Change: No change
Market closed Prices as at close on 27 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:145.00p
Buy:153.00p
Change: No change
Market closed Prices as at close on 27 November 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.

Contact details

Address:
20 Berkeley Square
LONDON
W1J 6EQ
United Kingdom
Telephone:
+44 (020) 72901050
Website:
https://arixbioscience.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 08 September 2020 08/09/20
AGM 04 June 2020 04/06/20
Final results 10 March 2020 10/03/20

General stock information

EPIC:
ARIX
ISIN:
GB00BD045071
Market cap:
£202.13 million
Shares in issue:
135.66 million
Sector:
General Financial
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Naseem Amin
    Executive Chairman of the Board
  • Marcus Karia
    Group Finance Director
  • Robert Lyne
    Chief Operating Officer, General Counsel, Company Secretary
  • Jonathan Tobin
    Managing Director
  • John Cassidy
    Investment Associate
  • Mark Chin
    Investment Director
  • Roberto Lacone
    Entrepreneur in Residence
  • Edward Rayner
    Investment Director
  • Christian Schetter
    Entrepreneur in Residence
  • Tim Xu
    Investment Associate

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.